P

Prime Medicine Inc
NASDAQ:PRME

Watchlist Manager
Prime Medicine Inc
NASDAQ:PRME
Watchlist
Price: 2.4 USD -2.44% Market Closed
Market Cap: 315.1m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

PRME Price Targets Summary
Prime Medicine Inc

Wall Street analysts forecast PRME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PRME is 7.5 USD with a low forecast of 1.52 USD and a high forecast of 12.6 USD.

PRME Lowest Forecast
Wall Street Target
1.52 USD
37% Downside
PRME Average Forecast
Wall Street Target
7.5 USD
213% Upside
PRME Highest Forecast
Wall Street Target
12.6 USD
425% Upside
Lowest
Price Target
1.52 USD
37% Downside
Average
Price Target
7.5 USD
213% Upside
Highest
Price Target
12.6 USD
425% Upside
Prime Medicine Inc Competitors:
Price Targets
EXEL
Exelixis Inc
5% Downside
MRUS
Merus NV
72% Upside
GILD
Gilead Sciences Inc
12% Upside
VITR
Vitrolife AB
61% Upside
EXEL
Exelixis Inc
5% Downside
MRUS
Merus NV
72% Upside
GILD
Gilead Sciences Inc
12% Upside
VITR
Vitrolife AB
61% Upside
BIIB
Biogen Inc
36% Upside
H
145020
Hugel Inc
15% Upside
688235
Beigene Ltd
13% Upside

Revenue
Forecast

Revenue Estimate
Prime Medicine Inc

For the last 4 years the compound annual growth rate for Prime Medicine Inc's revenue is -13%. The projected CAGR for the next 3 years is 117%.

-13%
Past Growth
117%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Prime Medicine Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Prime Medicine Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss
What are analyst estimates?

See Also

Summary
PRME intrinsic value, competitors valuation, and company profile.
DCF Valuation
PRME stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PRME stock valuation using valuation multiples.
Wall Street Estimates
PRME price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PRME stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PRME's stock price target?
Price Target
7.5 USD

According to Wall Street analysts, the average 1-year price target for PRME is 7.5 USD with a low forecast of 1.52 USD and a high forecast of 12.6 USD.

What is Prime Medicine Inc's Revenue forecast?
Projected CAGR
117%

For the last 4 years the compound annual growth rate for Prime Medicine Inc's revenue is -13%. The projected CAGR for the next 3 years is 117%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 263,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.